NEW YORK--(BUSINESS WIRE)--Penumbra, Inc. (NYSE:PEN) opened for trading today on the New York Stock Exchange (NYSE) under the ticker symbol “PEN” after its initial public offering. IMC is the Designated Market Maker for the company’s stock.
Adam Elsesser, Chairman, CEO and President, joined by members of Penumbra’s leadership team, commemorated the company’s public debut by inviting a stroke survivor to ring the NYSE Opening Bell®. They also visited the trading floor to watch the stock open.
Penumbra is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical need across two major markets, neuro and peripheral vascular. The conditions that the company’s products address include ischemic stroke, hemorrhagic stroke and various peripheral vascular conditions that can be treated through thrombectomy and embolization procedures.
“We’re pleased to welcome Penumbra to the NYSE’s community of the world’s leading companies,” said Garvis Toler, NYSE Head of Global Capital Markets. “Penumbra is an innovative, global company, developing and manufacturing medical devices which help save the lives of patients with serious conditions, including stroke. We congratulate the Penumbra team on its IPO and look forward to many more milestones with the company as part of the NYSE family of listed companies.”
“Penumbra is honored to have a patient who survived an acute ischemic stroke ring the NYSE Opening Bell to remind us of how our new technologies, such as the Penumbra System, save lives,” said Penumbra Chairman and CEO Adam Elsesser. “Patient stories such as this remind us why we work so hard every day to make impactful products and that’s what this is all about for us.”
The NYSE is home to many of the world's most iconic brands, technology business leaders and emerging growth companies shaping today's global economic landscape. For more information on listing on the New York Stock Exchange, visit https://www.nyse.com/why-nyse.
About NYSE Group
NYSE Group is a wholly-owned subsidiary of Intercontinental Exchange (NYSE: ICE), operator of the leading global network of exchanges and clearing houses. NYSE Group operates multi-asset exchanges, and a range of related data products and technology services. The company’s equity exchanges - the New York Stock Exchange, NYSE MKT and NYSE Arca - trade more U.S. equity volume than any other exchange group. NYSE is the global leader in capital raising for listed companies, including the majority of technology IPOs globally since 2012. The company’s equity options markets, NYSE Arca Options and NYSE Amex Options offer complementary market models. NYSE Group also provides comprehensive global connectivity services and a range of market data products to support efficient, transparent markets.
About Intercontinental Exchange
Intercontinental Exchange (NYSE:ICE) operates the leading network of regulated exchanges and clearing houses. ICE’s futures exchanges and clearing houses serve global commodity and financial markets, providing risk management and capital efficiency. The New York Stock Exchange is the world leader in capital raising and equities trading.
Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located at www.intercontinentalexchange.com/terms-of-use.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 - Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2014, as filed with the SEC on February 5, 2015.
Penumbra, Inc. is a global interventional therapies company that designs, develops, manufactures and markets innovative medical devices. The company has a broad portfolio of products that address challenging medical conditions and significant clinical need across two major markets, neuro and peripheral vascular. Penumbra has approximately 1,000 employees and sells its products to hospitals primarily through its direct sales organization in the U.S., most of Europe, Canada and Australia, and through distributors in select international markets.
SOURCE: Intercontinental Exchange